HOME >> BIOLOGY >> NEWS
Scripps research team discovers a chemical pathway that causes mice to overeat and gain weight

The Scripps Research team, led by neuroscientists Manuel Sanchez-Alavez and Tamas Bartfai, discovered that mice genetically altered to lack a molecule known as the EP3 receptor tend to be more active during their normal sleep cycle and to eat more. In the study, this led to weight increases of up to 30 percent relative to mice with the receptors.

The EP3 receptor is one of four types of receptors for prostaglandin E2 (PGE2), the most important inflammatory mediator that controls a variety of physiological functions including fever, fertility, and blood pressure. The most common anti-inflammatory and analgesic treatments like ibuprofen are aimed at reducing PGE2 signaling at all four prostaglandin receptors.

The absence of EP3 receptors has long been known to prevent fever response in mice, and it was this effect that the Scripps Research team was originally studying. Previous research on mice lacking the receptors had focused on fever inhibition until mice were about three months old. The team wanted to better understand the process by studying if fever inhibition continued later in life.

When the mice were four to five months old, the researchers made a startling discovery. The older mice still did not develop fever, but the researchers noticed that these mice were gaining weight.

"The experimental mice were clearly getting heavier than their wild type litter mates, the control mice," says Sanchez-Alavez. "We realized there was something interesting going on with these animals, so we started watching their behavior at night and during the day."

During continuous monitoring of temperature and motor activity, the researchers realized that the mice without the EP3 receptors were more active during the light hours-the nocturnal mice's "night"-and, more importantly, were eating during this time. The increased activity led to higher body temperatures, but this did not burn enough extra calories to balance the additi
'"/>

Contact: Marisela Chevez
mchevez@scripps.edu
858-784-2171
Scripps Research Institute
12-Feb-2007


Page: 1 2

Related biology news :

1. Scripps research scientists show protein accelerates breast cancer progression in animal models
2. Study led by Scripps Research scientist reveals little-known cell networks vital to circadian rhythm
3. Scripps research team sheds light on long-sought cold sensation gene
4. Scripps research study shows humans and plants share common regulatory pathway
5. Scripps research scientists identify new regulatory mechanism for critical protein signaling domain
6. Scripps research study reveals structural dynamics of single prion molecules
7. Scripps research scientists: Compounds show significant promise against potential bioweapon toxins
8. Scripps Research study reveals new function of protein kinase pathway in tumor suppression
9. Scripps Research study reveals new activation mechanism for pain sensing channel
10. NYU, Scripps finding offers new path for treatment of diabetes
11. Reduced body temperature extends lifespan in study from the Scripps Research Institute

Post Your Comments:
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/19/2015)... OXFORD, Conn. , March 19, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce market, ... featured in a news clip that aired this week on ... http://www.myfoxdc.com/ ) . In a segment "The Next ... smart wallet ,a new way to pay, and ,a really ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , ... a new 41,500 ft2 facility. The planned move will ... 16825 W. 116th St. in Lenexa, KS. The new ... laboratory space, will remain in the Kansas City metro area, ... than twenty years ago. Remaining in the Kansas City ...
(Date:4/21/2015)... April 21, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... multi-arm Phase 1 study of MM-141, a bispecific antibody ... an oral session by Dr. Mansoor Saleh , ... Annual Meeting in Philadelphia, PA. ... as a monotherapy and in combination with everolimus or ...
(Date:4/21/2015)... FOREST, Calif. , April 21, 2015 ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... today announced that Dr. Mark W. ... at the 3rd Annual BioLogistics Summit in ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 ... will sponsor and exhibit at the ACRP 2015 Global ... Lake City, Utah. The Association of Clinical Research Professionals ... clinical research conference solely focused on the conduct of ... training and development, and widely recognized industry certifications. , ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2
Cached News: